Literature DB >> 8073036

A mutational analysis of receptor binding sites of interleukin-1 beta: differences in binding of human interleukin-1 beta muteins to human and mouse receptors.

M G Grütter1, J van Oostrum, J P Priestle, E Edelmann, U Joss, U Feige, K Vosbeck, A Schmitz.   

Abstract

The 3-D crystal structure of interleukin-1 beta (IL-1 beta) has been used to define its receptor binding surface by mutational analysis. The surface of IL-1 beta was probed by site-directed mutagenesis. A total of 27 different IL-1 beta muteins were constructed, purified and analyzed. Receptor binding measurements on mouse and human cell lines were performed to identify receptor affinities. IL-1 beta muteins with modified receptor affinity were evaluated for structural integrity by CD spectroscopy or X-ray crystallography. Changes in six surface loops, as well as in the C- and N-termini, yielded muteins with lower binding affinities. Two muteins with intact binding affinities showed 10- to 100-fold reduced biological activity. The surface region involved in receptor binding constitutes a discontinuous area of approximately 1000 A2 formed by discontinuous polypeptide chain stretches. Based on these results, a subdivision into two distinct local areas is proposed. Differences in receptor binding affinities for human and mouse receptors have been observed for some muteins, but not for wild-type IL-1 beta. This is the first time a difference in binding affinity of IL-1 beta muteins to human and mouse receptors has been demonstrated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8073036     DOI: 10.1093/protein/7.5.663

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  6 in total

1.  XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases.

Authors:  Alexander M Owyang; Hassan Issafras; John Corbin; Kiran Ahluwalia; Paul Larsen; Elizabeth Pongo; Masahisa Handa; Arnold H Horwitz; Marina K Roell; Mary Haak-Frendscho; Linda Masat
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

Review 2.  Trends and future developments in the pharmacological treatment of acute ischaemic stroke.

Authors:  G J del Zoppo; S Wagner; M Tagaya
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

3.  Direct binding to integrins and loss of disulfide linkage in interleukin-1β (IL-1β) are involved in the agonistic action of IL-1β.

Authors:  Yoko K Takada; Jessica Yu; Masaaki Fujita; Jun Saegusa; Chun-Yi Wu; Yoshikazu Takada
Journal:  J Biol Chem       Date:  2017-10-13       Impact factor: 5.157

4.  Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties.

Authors:  Hassan Issafras; John A Corbin; Ira D Goldfine; Marina K Roell
Journal:  J Pharmacol Exp Ther       Date:  2013-11-05       Impact factor: 4.030

5.  Role of astrocytes in pathogenesis of ischemic brain injury.

Authors:  B Gabryel; H I Trzeciak
Journal:  Neurotox Res       Date:  2001-04       Impact factor: 3.911

6.  Structure and function of chicken interleukin-1 beta mutants: uncoupling of receptor binding and in vivo biological activity.

Authors:  Wen-Ting Chen; Wen-Yang Huang; Ting Chen; Emmanuel Oluwatobi Salawu; Dongli Wang; Yi-Zong Lee; Yuan-Yu Chang; Lee-Wei Yang; Shih-Che Sue; Xinquan Wang; Hsien-Sheng Yin
Journal:  Sci Rep       Date:  2016-06-09       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.